There were 60 (63.2%) male and 35 (36.8%) female patients, with a mean +/- SD age of 67.5 +/- 10.8 years. Comparison of the characteristics of the two groups revealed that the BiClamp((R)) group included significantly more cases of lobectomy by video-assisted thoracic surgery and far fewer completely lobulated lungs; 6 of 66 patients (9.1%) compared with 9 of 29 (31.0%) of the staple group. Except for 18 patients who underwent division using staples owing to thick parenchyma
of the interlobar fissure, we attempted to divide the fissure of 42 patients in the BiClamp((R)) group. Solo use of the BiClamp((R)) was possible for 25 of 60 patients (41.7%) with an incomplete fissure. Eight patients (13.3%) needed one staple cartridge in combination with BiClamp((R)), five (8.3%) needed two cartridges and four (6.7%) patients needed three (combined use). In most cases, except for right upper or middle lobectomy, the Selleckchem Etomoxir division of the interlobar fissure could be performed Selleck E7080 by sole use of the BiClamp((R)). Incidence
rates of prolonged air leakage and pneumonia were not significantly different between the two groups (respectively, 6.9 and 3.4% in the staple group vs 10.6 and 9.1% in the BiClamp((R)) group).
The study results demonstrate that the division of the interlobar fissure in pulmonary lobectomy with BiClamp((R)) is safe and feasible in most cases. While the results point out the limitation that division of the right upper or middle lobe may still be a challenge, they show the
potential benefit of staple reduction. Less use of staples results in reduced medical costs and carbon dioxide emission, contributing to ‘ecosurgery’, which ultimately conserves the global PD-1/PD-L1 Inhibitor 3 Immunology & Inflammation inhibitor environment.”
“A novel terpenoid coumarin, clausmarin-C ( 1), has been isolated from Clausena pentaphylla. Its structure has been established by extensive 1D- and 2D-NMR analysis and chemical transformation.”
“Objective: High frequency hearing loss following cisplatin chemotherapy is frequent in children and often necessitates the fitting of hearing aids. During therapy, hearing is usually monitored. Post-therapeutic follow-up does not routinely include monitoring of hearing, although there are indications that hearing thresholds can decline after therapy.
Methods: Pure-tone audiograms taken from 27 children (17 males, 10 females) treated with cisplatin at Muenster university hospital (mean age 9.84 years, standard deviation 3.67 years) including an audiological follow-up at least 6 months after therapy, were analyzed retrospectively.
Results: In follow-up tests after completion of therapy, 24.1% of all ears showed an increase in mean high frequency hearing thresholds (4-8 kHz). Post-therapeutic hearing deterioration was significant at 4 kHz and significantly more pronounced in children without measurable spontaneous otoacoustic emissions (SOAE) before therapy.
No related posts.